(re-post to improve clarity & accurately
depict who was involved in the study)
Follow-up 2:
- - -
May 19 2023
Tirzepatide improves body composition
across a range of adult age groups,
study shows
https://www.news-medical.net/news/20230519/Tirzepatide-improves-body-composition-across-a-range-of-adult-age-groups-study-shows.aspx
- - -
A new analysis of SURMOUNT-1, the first
Phase 3 study of tirzepatide in adults for
chronic weight management shows that
tirzepatide improves body composition
across a range of adult age groups.
... The efficacy and safety of tirzepatide,
a glucose-dependent insulinotropic poly-
peptide (GIP) and glucagon-like peptide-1
(GLP-1) receptor agonist, in people with
[BMI 27 or higher] was investigated in
SURMOUNT-1, the complete trial for ...
... which was published in NEJM in July
2022.
GIP and GLP-1 are hormones that are
involved in blood sugar control & body
weight regulation. After a person has
eaten, these hormones are secreted by
cells of the intestines and in turn cause
the secretion of insulin [in persons ...
... with a fully function pancreas]. Tirzep-
atide activates both the GLP-1 & GIP re-
ceptors, leading to improved blood sugar
control & enhanced satiety.
Tirzepatide is approved in the USA & the
European Union to treat Cellosis [old out-
dated name type 2 diabetes], but is not
yet approved for [BMI 30 & higher or per
the study, BMI 27 & higher] treatment in
any country.
The manufacturer of tirzepatide, Eli Lilly
& Company, intends to seek approval for
the drug as a [BMI 30 & higher or, per the
study, BMI 27 & higher] treatment from the
US Food and Drug Administration (FDA),
the European Union, & other territories
beginning in 2023.
[see article for details on individuals
without any of the 7 Disparate High Glu-
cose Conditions (DHGCs) who had a
BMI of 27 or higher that were involved
in the study]
On Saturday, March 4, 2023 at 9:33:27 AM UTC-6, _ wrote:
.> Follow-up:
.>
.> FDA approved tirzepatide to treat Cellosis (new clari-
.> fying name for type 2 diabetes) May 13 2022. In April
.> 2023, Lilly may submit it to FDA to be approved as a
.> weight loss drug, but I'm not sure who will & who won't
.> qualify to use the drug for that purpose. Also, current
.> information indicates many insurers won't cover the
.> drug for weight loss.
.>
.> - - -
.> March 3 2023
.>
.> Tirzepatide: ... a new era of weight loss — because
.> this one works. Scientists are still figuring out why
.> tirzepatide causes weight loss. One theory is that
.> they “accidentally” created a new hormone.
.>
https://bigthink.com/health/tirzepatide-novel-obesity-drug-actually-works/
.> - - -
.>
.> ... Semaglutide, approved in 2021, helped 86% of
.> patients drop at least 5% of their body weight, with
.> an average weight loss of 15% (compared to 2.4%
.> for placebo). Since its approval, semaglutide (sold
.> under the brand name Wegovy) has been hailed as
.> a “transformative breakthrough” in the battle against
.> [stoutness].
.>
.> However, the new drug, tirzepatide, has left semag-
.> lutide in its shadow: 91% of patients saw a reduction
.> of at least 5%, with an average weight loss of 21% for
.> the highest dose (compared to 3.1% for placebo).
.>
.> ... Eli Lilly, tirzepatide’s manufacturer, doesn’t need
.> to understand why exactly the drug works in order
.> to bring it to market. The company plans to apply
.> for drug approval (as a weight loss drug?) in April
.> 2023.
.>
.> Tirzepatide was approved to treat Cellosis (see
.> description of Cellosis in post below for details
.> on what Cellosis is) on May 13 2022:
.>
https://www.google.com/search?q=tirzepatide+fda+approval
.>
.>
https://www.google.com/search?q=Tirzepatide
.>
.> All of the tirzepatide articles that use diabetes
.> without clarifier, fact is they're all solely referring
.> to Cellosis (see previous post below for details).
.>
.> As for BMI 30 & above, see the following graphic
.> for new preferred clarifying words to put an end
.> to the pejorative nature of most weight words:
.>
.> BMI, Waist Circumference, & Associated Disease Risks
.>
https://prohuman.net/pix2/BMI-WaistCircumference-Cellosis&Hypertension&CardiovascularDisease-.Risk.jpg
.>
.> As for what weight the use of tirzepatide would
.> be approved for, I don't know. As for whether or
.> not it might be approved for Ample weight indi-
.> viduals (BMI 25 to 29.9), as a preventative for
.> further weight gain, I don't know.
.>
.> As for whether or not it might be approved for
.> Average weight individuals (BMI 18.5 to 24.9)
.> who simply want to be thinner, I doubt it but I
.> don't know.
.>
.> As for how high the risk is for possible thyroid
.> tumors, I don't know.
.>
.> Its current approval says it's not for use to treat
.> Islit (Insulinitis - see description in previous post
.> below) but I don't know if those with Islit might
.> be able to use tirzepatide to lose weight or if the
.> use of tirzepatide would increase the hypogly-
.> cemia risk for those with Islit & for those with ...
.>
.> ... any other Disparate High Glucose Condition
.> who are using any medications that cause hypo-
.> glycemia.
.>
.> Side effects & other medication information:
.>
https://uspl.lilly.com/mounjaro/mounjaro.html#mg
> On Wednesday, March 3, 2021 at 9:14:09 AM UTC-6, _ wrote:
/~> .> - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
/~> .> Cellosis, superior new clarifying name
/~> .> for continued insulin production unable to
/~> .> keep glucose level < HbA1c 6.5, modest
/~> .> risk usually at weight with BMI 25-29.9, a
/~> .> greater risk with weight BMI = or > 30, ...
/~> .>
/~> .> ... greatest risk with weight BMI 35 or higher
/~> .> with the highest risk with BMI in the stratos-
/~> .> phere; however, old age increases risk apart
/~> .> from weight issues, and high carb diets as
/~> .> well as sparse exercise increases risk even ...
/~> .>
/~> .> ... at BMI < 25. Inherited polygenetic risk
/~> .> (from one or both parents having Cellosis)
/~> .> also can play a causal factor.
/~> .> - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
/~> .>
/~> .> o Phase 3 clinical trials comparing the use of
/~> .> Tirzepatide injections in Cellosis individuals
/~> .> who use either Degludec or Glargine insulin
/~> .> injections with or without Metformin
/~> .>
/~> .> o Tirzepatide injections reduced HbA1c by an
/~> .> average of 2.5 percentage points and led to a
/~> .> weight loss of 24-28 pounds
/~> .>
/~> .> o Tirzepatide injections reduced high incidence
/~> .> of hypoglycemia dramatically
/~> .>
/~> .> o Unknown when or if Tirzepatide injections may
/~> .> be approved to treat Cellosis and/or BMI 30 and
/~> .> above
/~> .>
/~> .> February 17 2021
/~> .>
https://diatribe.org/breaking-news-tirzepatide-most-buzzworthy-drug-development
/~> .>
/~> .> February 17 2021
/~> .>
https://finance.yahoo.com/news/tirzepatide-significantly-reduced-a1c-body-114500358.html
/~> .>
/~> .> February 22 2021
/~> .> Tirzepatide and the Search for Better
/~> .> BMI 30 and Above Treatment
/~> .>
https://conscienhealth.org/2021/02/tirzepatide-and-the-search-for-better-obesity-treatment/
/~> .>
/~> .> March 3 2021
/~> .>
https://diabetestimes.co.uk/tirzepatide-reduces-hba1c-levels-and-body-weight-in-people-with-type-2-diabetes/
/~> .>
/~> .> *** *** *** *** *** *** *** *** *** *** *** ***
/~> .>
/~> .> - - -
/~> .> diabetes / diabetic without a clarifier,
/~> .> diabetes / diabetic guessing required
/~> .>
https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
/~> .> - - -
/~> .>
/~> .> Pro-Humanist FREELOVER, Insulitis Islit
/~> .> (Islit, the abbreviation for Insulinitis) since
/~> .> age 5, March 1961, promoting replacement
/~> .> of all of the outdated ancient confusing mis-
/~> .> leading diabetes / diabetic words & phrases
/~> .> & the confusing reactive hypoglycemia ...
/~> .>
/~> .> ... phrase with new superior clarifying noncon-
/~> .> fusing nonmisleading words & phrases & def-
/~> .> initions which were initially first proposed in
/~> .> May, 2010:
/~> .>
/~> .> Diabetes Bubble / Diabetes Bubble Burst
/~> .> (outstanding)
https://prohuman.net/diabetesbubblediabetesbubbleburst.htm
/~> .>
/~> .> C.ure I.nsulinitis A.ssociation
/~> .> (hopefully)
https://prohuman.net/cureinsulinitisassociation.htm
/~> .>
/~> .> Glucose Anomalies Research regarding
/~> .> Potential Cures / Improvements in Treatments
/~> .> (hopefully)
https://prohuman.net/glucoseanomaliesresearch.htm
/~> .>
/~> .> Insulinitis (Islit) is the near-total to total
/~> .> loss of endogenous insulin, requires
/~> .> multiple daily dosages of basal & bolus
/~> .> insulin to try to stay alive, every dosage
/~> .> a high risk in that severe hypoglycemia
/~> .> kills an estimated 5% to 11% Islit indivi-
/~> .> duals.
/~> .>
/~> .> There are 15 specific types of Insulinitis
/~> .> (Islit) that are rapid-onset, and 1 specific
/~> .> type (Latent Autoimmune Islit) that is slow
/~> .> onset.
/~> .>
https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
/~> .>
/~> .> - - -
/~> .>
/~> .> As for the most widespread High Glucose
/~> .> Conditions, 20 specific types of Cellosis
/~> .> (new clarifying name for type 2 diabetes)
/~> .> are unpreventable & nonreversible (thus
/~> .> far).
/~> .>
/~> .> The only specific type of ANY of the over
/~> .> 80 disparate specific types of High Glu-
/~> .> cose Conditions that is preventable (in
/~> .> many, with lifestyle changes) & reversible
/~> .> (possible if action is taken up to 10 years
/~> .> after diagnosis), Preventable Cellosis.
/~> .>
/~> .> Due to the slow onset of Cellosis, typic-
/~> .> ally, the prestage with good chance of
/~> .> Cellosis prevention = PreCellosis (the
/~> .> old confusing name is prediabetes), the
/~> .> HbA1c slightly above normal (5.7 to 6.4
/~> .> in those with no High Glucose Condition).
/~> .>
/~> .> *** *** *** *** *** *** *** *** *** *** *** ***